Shanghai Pharmaceuticals Holding (601607.SH): The listing application for Lacosamide API has been approved.
Connecting global capital markets
Announcement: Shanghai Pharmaceuticals Holding (601607.SH) announced that its wholly-owned subsidiary Shangyao Kangli (Changzhou) Pharmaceuticals Co., Ltd. ("Shangyao Kangli") has received the "Chemical Raw Material Drug Market Application Approval Notice" (Notice No.: 2023YS00679) issued by the State Drug Administration ("National Drug Administration") for its drug Lakaosha'an. The drug has been approved for production.
Related Articles
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
Cui Dongshu: By 2025, the total national second-hand car transaction volume will be 20.11 million units, an increase of 2.5% year-on-year.
Oracle’s Up-to-$50 Billion 2026 Funding Plan Signals the Next Phase of the AI Data-Center Buildout
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
Cui Dongshu: By 2025, the total national second-hand car transaction volume will be 20.11 million units, an increase of 2.5% year-on-year.
Oracle’s Up-to-$50 Billion 2026 Funding Plan Signals the Next Phase of the AI Data-Center Buildout
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
